Show simple item record

dc.contributor.authorTurhal, Nazım Serdar
dc.date.accessioned2016-05-05T06:42:00Z
dc.date.available2016-05-05T06:42:00Z
dc.date.issued2014
dc.identifier.issn0300891
dc.identifier.urihttp://goo.gl/ML0ZEx
dc.identifier.urihttp://hdl.handle.net/11424/4515
dc.description.abstractBackground. A high-risk group of patients with stage II colon cancer has been identified by the results of studies in Western populations. The aim of this study was to investigate the prognostic factors of adjuvant chemotherapy in Turkish patients with stage II colon cancer. Methods. A total of 554 stage II colon cancer patients were retrospectively enrolled in the study. Three hundred fifty-three patients had received adjuvant chemotherapy (5-FU-LV, FOLFOX or FLOX) and 201 had received no adjuvant chemotherapy. T4 tumor stage, lymphovascular invasion, perineural invasion, bowel obstruction and/or perforation, <12 harvested lymph nodes, and poor differentiation were defined as high-risk factors. Results. The median age of the patients was 62 years (range 26-88). The median disease-free survival (DFS) was 58.1 months (95% CI, 47.6 months to 68.5 months) in the non-treatment group and has not been reached in the treatment group (P <0.01). In univariate analysis, patient age >60 years and T4 tumor stage were statistically significant factors that affected DFS as poor prognostic factors. Adjuvant chemotherapy reduced the risk of recurrence with statistical significance (P <0.01). In multivariate analysis, patient age >60 years and T4 tumor stage were independent risk factors affecting DFS. In addition, adjuvant chemotherapy was an independent favorable prognostic factor for DFS (P <0.01). Conclusions. Clinical and pathological risk factors in patients with stage II colon cancer may be different in the Turkish population compared to other populations. Further prospective studies in colon cancer are needed to understand the differences in biology and risk factors between races. Copyright - Il Pensiero Scientifico Editore.en_US
dc.language.isoengen_US
dc.relation.isversionof10.1700/1491.16397en_US
dc.rightsinfo:eu-repo/semantics/restrictedAccessen_US
dc.subjectAdjuvant therapy; Colon cancer; Prognostic factorsen_US
dc.titleDo high-risk features support the use of adjuvant chemotherapy in stage II colon cancer? A Turkish Oncology Group studyen_US
dc.typearticleen_US
dc.relation.journalTumorien_US
dc.contributor.departmentDepartment of Medical Oncology, Medical Faculty, Marmara Universityen_US
dc.identifier.volume100en_US
dc.identifier.issue2en_US
dc.identifier.startpage143en_US
dc.identifier.endpage148en_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record